LONA · LeonaBio, Inc.
$7.94
+0.05 (+0.63%)
At close · Aug 28
Going-concern doubt
— flagged Aug 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“Based upon the Company's current operating plan, it estimates that its $51.1 million of cash, cash equivalents and investments at June 30, 2026 may not be sufficient to fund its operating expenses and capital expenditure requirements through at least the next 12 months which raises substantial doubt as to our ability to continue as a going concern following the date of this Quarterly Report on Form 10-Q.”View the 10-Q filed Aug 14, 2026
Market Cap
$74.81M
Shares
9.42M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$105.61M
-8.9%
FY2025
Diluted EPS
-$24.70
+1.9%
FY2025
Operating Cash Flow
-$45.73M
+52.9%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 |
|---|---|---|---|---|---|---|---|---|
| $33.5M | $17.5M | $70.68M | $93.79M | $61.46M | $42.79M | $13.29M | $3.79M | |
| $21.27M | $16.68M | $26.09M | $33.3M | $32.55M | $21.23M | $6.71M | $1.66M | |
| $122.11M | $102.27M | $100.9M | $125.47M | $104.02M | $64.02M | $20M | $5.45M | |
| -$122.11M | -$102.27M | -$100.9M | -$125.47M | -$104.02M | -$64.02M | -$20M | -$5.45M | |
| — | — | — | — | — | $3000 | $367K | $346K | |
| $1.55M | $1.24M | $3.96M | $7.64M | $3.22M | $334K | -$1.28M | -$466K | |
| — | — | — | — | — | — | -$19.96M | -$5.16M | |
| — | $0 | — | — | — | — | — | — | |
| -$141.46M | -$105.61M | -$96.94M | -$117.67M | -$95.64M | -$54.85M | -$19.96M | -$5.16M | |
| -$141.46M | -$105.61M | -$96.59M | -$116.07M | -$97.21M | -$55.27M | -$19.92M | -$5.16M | |
| USD/shares | -$23.11 | -$24.70 | -$25.19 | -$30.90 | -$25.30 | -$14.90 | — | — |
| USD/shares | -$23.11 | -$24.70 | -$25.19 | -$30.90 | -$25.30 | -$14.90 | — | — |
| shares | — | 4.28M | 3.85M | 3.8M | 3.77M | 3.69M | 1.2M | 356.68K |
| shares | — | 4.28M | 3.85M | 3.8M | 3.77M | 3.69M | 1.2M | 356.68K |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 4.91×
EV/EBIT
—
Peer median 12.40×
P/E (TTM)
—
Peer median 10.58×
Peer medians compare against the 297 similar-size Biotechnology companies (of 524 listed).
Key facts
CIK
1620463
CUSIP
04746L203
13F (30d)
43 filings
42 filers
Visit website
Investor relations